REG - Avacta Group PLC - Block Listing Six Monthly Return

AvactaAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260428:nRSb0751Ca&default-theme=true

RNS Number : 0751C  Avacta Group PLC  28 April 2026

 

 

 

Block Listing Six Monthly Return

 

 

LONDON and PHILADELPHIA - April 28, 2026 Avacta Therapeutics (AIM: AVCT,
'the Company'), a clinical stage biopharmaceutical company developing
pre|CISION®, a tumor-activated oncology delivery platform, today makes the
following notification pursuant to Schedule Six of the AIM Rules for Companies
regarding its existing block admission arrangements:

 

 Name of applicant:                                                                  Avacta Group plc
 Name of scheme:                                                                     EMI scheme
 Period of return:                         From:                                     28 October 2025          27 April 2026
 Balance of unallotted securities under scheme(s) from previous return:              124,558
 Plus:   The amount by which the block scheme(s) has been increased since            nil
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                 56,116
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:         68,442

 

 Name of applicant:                                                                     Avacta Group plc
 Name of scheme:                                                                        LTIP/ESOS scheme
 Period of return:            From:                                                     28 October 2025            27 April 2026
 Balance of unallotted securities under scheme(s):                                      1,183,662
 Plus:   The amount by which the block scheme(s) has been increased since               nil
 the date of the last return (if any increase has been applied for):
 Less:   Number of securities issued/allotted under scheme(s) during                    874,500
 period (see LR3.5.7G):
 Equals:   Balance under scheme(s) not yet issued/allotted at end of period:            309,162

  Name of contact:                                         Brian Hahn, Company Secretary
 Telephone number of contact:                              + 44 (0) 1904 217070

 

Ends-

 

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                   https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer        via Cohesion Bureau

 Strand Hanson Limited (Nominated Adviser)          www.strandhanson.co.uk (http://www.strandhanson.co.uk)

 James Harris / Chris Raggett / James Dance

 Zeus (Broker)                                      www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry / Dominic King

 Cohesion Bureau                                    avacta@cohesionbureau.com (mailto:avacta@cohesionbureau.com)

 Communications / Media / Investors

 Richard Jarvis

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies through its proprietary pre|CISION(®)
platform. pre|CISION(®) is a payload delivery system based on a
tumor-specific protease (Fibroblast Activation Protein or FAP) that is
designed to concentrate highly potent payloads in the tumor microenvironment
while sparing normal tissues. Avacta's innovative pre|CISION(®) peptide drug
conjugates (PDC) are a novel entry to the XDC drug class, leveraging the
success of antibody drug conjugates with alternative methods of delivery
beyond antibodies.

 

Our pre|CISION(®) PDCs leverage this tumor-specific release mechanism to
provide unique benefits over traditional antibody drug conjugates, releasing
active payload in the tumor and reducing systemic exposure and toxicity which
enables dosing to be optimized to deliver the best outcomes for patients. The
lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled
pre|CISION(®) version of doxorubicin that delivers the payload directly in
the tumor with limited peripheral blood exposure and has demonstrated
preliminary activity in tumor types sensitive to doxorubicin including
salivary gland cancer and soft tissue sarcoma.

 

About FAP-Exd (AVA6103)

 

AVA6103 is the second clinical candidate and is the first asset in the
pipeline based on the Gen Two innovative pre|CISION(®) sustained release
mechanism that provides for prolonged release of payload directly in the
tumor, minimizing systemic exposure.  AVA6103 is being evaluated in the
FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS).
Preclinical data suggest this approach has optimized payload delivery with a
high intratumoral concentration and prolonged exposure of released payload in
the tumor, coupled with limited systemic exposure to the released payload.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUQPCUPQGWM



            Copyright 2019 Regulatory News Service, all rights reserved